Fractyl Health (GUTS) FCF Margin (2023 - 2024)
Fractyl Health (GUTS) recorded quarterly FCF Margin of 575566.67% in Q4 2024, down 341.48% on a QoQ basis from 130371.43% in Q3 2024, and down 42220952.0% YoY from N/an in Q1 2024.
Powered by 
Analysis
Fractyl Health (GUTS) FCF Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has reported FCF Margin for 2 consecutive years, with 575566.67% the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, FCF Margin fell 42220952.0% year-over-year to 575566.67%; the trailing twelve-month figure through Dec 2024 stood at 72350.54% (down 3636554.0% YoY), and the FY2024 full-year result was 72350.54%, down 3636554.0% from the prior year.
- FCF Margin was 575566.67% for Q4 2024 at Fractyl Health, down from 130371.43% in the prior quarter.
- The five-year high for FCF Margin was 16265.28% in Q2 2023, with the low at 575566.67% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.08 Bn | 174.48 Bn | 7.27 Bn | 15.81% |
| 2 | Intuitive Surgical | 127.86 Bn | 122.64 Bn | 1.96 Bn | 32.79% |
| 3 | Medtronic | 117.15 Bn | 108.33 Bn | 6.34 Bn | 13.22% |
| 4 | Stryker | 103.82 Bn | 100.34 Bn | 4.50 Bn | 16.07% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 23.50% |
| 6 | Edwards Lifesciences | 49.76 Bn | 45.51 Bn | 1.35 Bn | 33.60% |
| 7 | Alcon | 32.95 Bn | 31.49 Bn | 1.68 Bn | 21.78% |
| 8 | Dexcom | 32.22 Bn | 30.27 Bn | 830.00 Mn | 14.10% |
| 9 | Steris | 20.71 Bn | 20.23 Bn | 684.20 Mn | 18.73% |
| 10 | Fractyl Health | 102.41 Mn | 102.41 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -575,566.67% |
| Sep 30, 2024 | -130,371.43% |
| Jun 30, 2024 | -44,179.07% |
| Mar 31, 2024 | -38,696.97% |
| Dec 31, 2023 | -153,357.14% |
| Sep 30, 2023 | -31,016.67% |
| Jun 30, 2023 | -16,265.28% |
| Mar 31, 2023 | -191,400.00% |